1050477-30-9
Chemical Structure
(R)-Finerenone
Synonym(s): (R)-BAY 94-8862
- CAS No.: 1050477-30-9
- Formula:C21H22N4O3
- Molecular Weight:378.42
IUPAC Name: (R)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
InChIKey: BTBHLEZXCOBLCY-KRWDZBQOSA-N
SMILES: O=C(C1=C(C)NC2=C(C(OCC)=NC=C2C)[C@H]1C3=CC=C(C#N)C=C3OC)N
Biological Activity: (R)-Finerenone ((R)-BAY 94-8862) is the R-isomer of Finerenone (HY-111372). Finerenone is a third-generation selective, orally active, non-steroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Compared with glucocorticoid receptors (GR), androgen receptors (AR), and progesterone receptors (AR), Finerenone shows good selectivity (> 500-fold). Finerenone has potential application prospects in studies of heart and kidney diseases, such as type 2 diabetes and chronic kidney disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Finerenone | 99.70% | (R)-Finerenone ((R)-BAY 94-8862) is the R-isomer of Finerenone (HY-111372). Finerenone is a third-generation selective, orally active, non-steroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Compared with glucocorticoid receptors (GR), androgen receptors (AR), and progesterone receptors (AR), Finerenone shows good selectivity (> 500-fold). Finerenone has potential application prospects in studies of heart and kidney diseases, such as type 2 diabetes and chronic kidney disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [Content Brief]
- [2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9. [Content Brief]
Keywords
